Search

Researchers at TOBB University of Economics and Technology have conducted a study on the effects of micro ribonucleic acids (miRNAs) in inborn errors of metabolism (IEM) and potential treatment strategies. MiRNAs are short non-coding RNA molecules that play a crucial role in regulating gene expression. The study suggests that further research on miRNA expression related to IEM could lead to the identification of new biomarkers for diagnosis, progression, and prognosis of diseases. This research provides insights into the potential use of miRNAs as therapeutics to address cellular dysfunctions associated with inherited metabolic diseases. [Extracted from the article]

Researchers from Guizhou Medical University conducted a study on miRNA-22-3p and its impact on nasopharyngeal carcinoma (NPC). The research found that miRNA-22-3p inhibits cell viability and metastasis of NPC by targeting Foxp1. This study suggests that miRNA-22-3p could be a valuable biomarker for NPC therapy, providing new insights into potential treatment options for this type of cancer. The research was supported by Guiyang Science and Technology Plan Projects and has been peer-reviewed for accuracy and validity. [Extracted from the article]

A patent was issued for compositions and processes related to the targeted delivery, expression, and modulation of coding ribonucleic acids in tissue by Combined Therapeutics Inc. The invention focuses on delivering messenger RNA (mRNA) to cells in a target organ using microRNA-mediated expression modulation to achieve differential expression in different cell types within the organ. This technology aims to enhance or modulate the function of various therapies, such as oncolytic viral therapy, chemotherapy, antibody therapy, or radiotherapy, by selectively expressing mRNA in specific cells, like cancerous cells, to increase therapeutic efficacy while reducing side effects. The patent provides detailed information on the composition, delivery particles, mRNA sequences, and miRNA binding site sequences used in this innovative approach to cancer gene therapy. [Extracted from the article]

A study conducted at Hokuto Hospital in Japan introduced a noninvasive urinary extracellular vesicle miRNA-based assay for detecting pancreatic cancer from early to late stages. The research involved collecting urine samples from patients with pancreatic cancer and non-cancer participants, analyzing miRNAs, and developing a machine learning model for detection. The study showed promising results with high sensitivity and specificity, indicating the potential for early detection of pancreatic cancer using miRNA-based therapy. The researchers aim to make this assay more accessible to a broader population, particularly in areas with limited hospital access, to improve treatment outcomes through population screening. [Extracted from the article]

Researchers at the University of Kashan in Iran have conducted a study on the potential of microRNAs (miRNAs) as biomarkers and therapeutic targets for cancer. The research highlights the importance of miRNAs in cancer research, emphasizing their role as diagnostic and prognostic indicators. MiRNA-based therapies show promise in improving patient outcomes by providing personalized approaches to cancer treatment and understanding mechanisms of chemotherapy resistance. The study suggests that miRNAs could revolutionize cancer management through liquid biopsies, leading to more effective therapies and better patient outcomes. [Extracted from the article]

Researchers from the University of Nevada have conducted studies on miRNA-based therapy, focusing on the dual roles of miR-10a-5p and miR-10b-5p in various cancers. These microRNAs can act as both tumor suppressors and oncogenes, influencing cancer progression by targeting specific genes. The research explores the molecular mechanisms of miR-10a/b-5p and their potential as therapeutic targets for cancer treatment, aiming to advance understanding of their roles in tumor biology and innovative therapies. Financial support for this research came from RosVivo Therapeutics Inc. [Extracted from the article]

Researchers at Xuzhou Central Hospital in China have developed an innovative electrochemical sensing platform for detecting microRNA (miRNA) based on the synthesis of copper nanoclusters. This platform allows for sensitive detection of miRNA 21 extracted from cancer cells with a detection limit of 36 aM. The method is cost-effective, user-friendly, and has potential applications in fundamental research and disease diagnosis. The study was funded by various organizations and has been peer-reviewed. [Extracted from the article]

A recent study conducted by the University of Campania Luigi Vanvitelli in Naples, Italy, explores the potential of miRNA-based therapy in treating Autosomal Dominant Polycystic Kidney Disease (ADPKD) in pediatric patients. The research highlights the importance of early identification and treatment of ADPKD in children and adolescents to ensure better long-term outcomes. By investigating the role of microRNAs in regulating gene expression and their potential as biomarkers and therapeutic targets, the study aims to pave the way for innovative treatment strategies for young patients with ADPKD. This research, which has been peer-reviewed, provides valuable insights into the use of miRNA-based therapy as a targeted treatment approach for pediatric ADPKD patients. [Extracted from the article]

Researchers from Technological University conducted a study on miRNA-based therapy to explore its potential in regulating obesity and diabetes. The study focused on identifying dysregulated miRNAs and cytokines in obese and diabetic patients compared to controls. The findings suggest that these molecular targets could be used for personalized miRNA-based therapeutics for obesity and diabetes. The research was published in the SURE Journal and is available for further reading. [Extracted from the article]

Researchers from the Faculty of Medicine in Katowice, Poland, conducted a study on the differential expression of genes and miRNAs involved in the PI3K/AKT/mTOR signaling pathway in breast cancer subtypes. They found that key genes such as COL1A1, COL4A1, PIK3CA, PIK3R1, and mTOR were overexpressed, particularly in aggressive subtypes like triple-negative breast cancer (TNBC). The study suggests that miRNA regulators of the pathway, such as miR-190a-3p, miR-4729, and miR-19a-3p, play crucial roles in breast cancer progression and could serve as potential biomarkers for diagnosis and treatment. Further validation in functional studies is needed to explore targeted therapies aimed at modulating this critical pathway to improve breast cancer outcomes. [Extracted from the article]

The article discusses the development of a novel miRNA inhibition platform called "miRNA Locker" using the Overlapped Oligo Assembly (OOA) method. This platform constructs stable single-stranded DNA structures to inhibit miRNAs, demonstrating effectiveness in reducing miRNA levels and inducing changes in gene expression. The study highlights the potential of miRNA Lockers as a versatile tool for studying miRNA function and advancing miRNA-based therapies, particularly in cancer research. The preprint has not been peer-reviewed, and more information can be found on biorxiv.org. [Extracted from the article]

A study on miRNA-based therapy in diffuse large B-cell lymphoma (DLBCL) was conducted by researchers at the Digital Health Center in Moscow, Russia. The research focused on the dysregulation mechanisms of p53-responsive microRNAs in DLBCL patients, highlighting the potential therapeutic opportunities in cancer treatment. The study emphasized the role of microRNAs in regulating gene expression and their impact on tumorigenesis processes, offering insights into new bioinformatics tools and databases for DLBCL research. For more information, the full article can be accessed through PeerJ, with contact information available for the lead researcher, Yuriy L. Orlov, at the Digital Health Center in Moscow. [Extracted from the article]

A recent report from the Second Affiliated Hospital of Jiaxing University in China discusses the role of microRNAs (miRNAs) in pancreatic cancer drug resistance. The review highlights how miRNAs influence treatment efficacy in pancreatic cancer and explores their potential as therapeutic tools. Despite promising developments, challenges such as specificity and effective delivery of miRNA-based therapeutics remain. The research aims to provide a critical perspective on current findings and suggest future directions for leveraging miRNA-based interventions in the fight against pancreatic cancer. [Extracted from the article]

Recent research from the University of Leeds focuses on miRNA-based therapy to enhance oncolytic virotherapy by reprogramming the tumor microenvironment. The study highlights the role of tumor-associated macrophages (TAMs) in promoting tumor growth and immunosuppression in ovarian cancer. By delivering specific miRNAs to TAMs using oncolytic viruses, researchers were able to reverse their pro-tumor activity and improve the efficacy of cancer immunotherapies. This approach shows promise in enhancing anti-tumor immune responses and potentially improving outcomes for ovarian cancer patients. [Extracted from the article]

A study conducted by researchers at East China Normal University in Shanghai, China, explores the use of DNA logic circuits to enhance the selective fusion of protocells for the detection of exosomal microRNAs (miRNAs) in cancer diagnosis. The research focuses on developing a biosensing strategy that accurately detects tumor-related miRNAs in clinical samples, showcasing promising results for miRNA-based liquid biopsy in cancer diagnosis. Funded by various organizations, this peer-reviewed study highlights the potential applications of DNA logic circuits in boosting selective fusion for reliable detection of exosomal miRNAs. [Extracted from the article]

A patent application by inventors from Seoul, South Korea, has been made available online for a pharmaceutical composition using a microRNA (miRNA) inhibitor for the prevention or treatment of vascular smooth muscle cell proliferative diseases. The invention focuses on regulating miRNAs associated with the over-proliferation of smooth muscle cells in arteries, aiming to address conditions like atherosclerosis and restenosis. The composition contains specific miRNA inhibitors and may be administered alone or in combination with other medications, potentially offering a targeted approach to prevent vascular diseases. [Extracted from the article]

A recent study conducted at Sichuan University in Chengdu, People's Republic of China, focused on miRNA-based therapy for acute liver and kidney injury. The research developed an enzyme-responsive nanoparachute (NP) to deliver miRNA-125 to affected tissues, regulating specific pathways and proteins to inhibit oxidation, prevent cell cycle arrest, and reduce apoptosis in liver and kidney cells. The study concluded that this strategy shows promise as a potential treatment for acute liver and kidney injury, offering new insights into biotechnology and therapeutic approaches. [Extracted from the article]

Researchers from the University of Thessaly in Larisa, Greece, have conducted a study on miRNA-based therapy for testicular germ cell tumors (TGCT). The study aimed to differentiate between histologic subtypes of TGCT using miRNA profiling and assess prognostic implications. Results showed that specific miRNA signatures could aid in the differential diagnosis and prognostic stratification of TGCT, with potential treatment implications. This research highlights the clinical value of miRNA-based therapy in the management of TGCT. [Extracted from the article]

A study conducted at Xinxiang Medical University in Henan, China, explored the use of extracellular vesicles from cardiomyocytes to reprogram cardiac fibroblasts into myocardial-like cells, potentially aiding in cardiac regeneration. The research involved cell experiments and animal studies, showing promising results in terms of myocardial infarction therapy and cardiac function improvement. The study highlighted the role of miRNA-133 in this reprogramming process. This research has been peer-reviewed and offers valuable insights into biotechnology-based miRNA therapy for heart diseases. [Extracted from the article]

A study conducted at the University Hospital of Leipzig in Germany focused on miRNA-based therapy for relapsed Acute Myeloid Leukemia (AML) patients. The research aimed to identify molecular determinants of chemoresistance and potential therapeutic targets for restoring chemosensitivity. By analyzing microRNA profiles in bone marrow samples, researchers found significant differential expression of microRNAs between diagnosis and relapse, with upregulation of the FoxO signaling pathway confirmed through gene expression analysis. This study highlights the potential of microRNA-based pathway prediction in identifying signaling pathways as targets for therapeutic intervention in AML patients. [Extracted from the article]

Researchers from Kermanshah University of Medical Sciences in Iran have explored the relationship between microRNAs (miRNAs) and CD8+ T cells in various cancers, highlighting the potential for manipulating miRNA expression to enhance anti-tumor immunity and improve cancer immunotherapy outcomes. The study delves into how specific miRNAs influence CD8+ T cell function and how dysregulation can lead to immune evasion and hinder anti-tumor immunity. The findings suggest that targeting miRNAs to manipulate CD8+ T cell activity could lead to the development of novel and improved cancer immunotherapies. [Extracted from the article]

Researchers at the University of Palermo have conducted a study on miRNA-based therapy, focusing on the communication between the central nervous system and peripheral organs through extracellular vesicles (EVs). These EVs deliver microRNAs (miRNAs) that can modulate the expression profiles of recipient cells, potentially influencing their functions. The research suggests that understanding this process could offer valuable insights for treating neurological and systemic diseases. For more information, readers can refer to the article "Brain-Periphery Axes: The Potential Role of Extracellular Vesicles-Delivered miRNAs" published in Biology. [Extracted from the article]

A recent report from the University of Campania 'Luigi Vanvitelli' in Naples, Italy, discusses the use of self-assembling nanoparticles to deliver miRNA-603 and miRNA-221 in the treatment of glioblastoma, a highly aggressive brain cancer. The study aims to overcome resistance to temozolomide therapy, a common treatment for glioblastoma. Preliminary results show promising outcomes in reducing tumor growth and improving treatment efficacy. The research has been peer-reviewed and provides valuable insights into potential new strategies for combating chemoresistance in glioblastoma. [Extracted from the article]

A recent report from the University of Illinois highlights the significance of microRNAs (miRNAs) in maintaining cellular homeostasis by regulating gene expression. The 2024 Nobel Prize in Medicine and Physiology recognized the discovery of miRNAs, paving the way for potential advancements in miRNA-based therapies for various diseases. The research emphasizes the importance of further exploration and development of miRNA-based treatments, anticipating a surge in research and drug discovery in this field. For more information, readers can refer to the article "Microrna Nobel Prize: Timely Recognition and High Anticipation of Future Products-a Prospective Analysis" in the International Journal of Molecular Sciences. [Extracted from the article]

Researchers at Comenius University in Slovakia have published new study findings on miRNA-based therapy, highlighting the essential role of microRNAs in regulating gene expression in human cells. The article traces the history of miRNAs from their discovery in nematodes to their potential as a therapeutic tool, culminating in the Nobel Prize in Physiology or Medicine in 2024. The research also discusses the current limitations hindering the clinical application of miRNA-based therapy. For more information, readers can refer to the article "History of Micrornas: From Gene Controlling Development of Nematodes to a Promising Tool for Molecular Therapy" in Acta Medica Martiniana. [Extracted from the article]

Researchers at Mazandaran University of Medical Sciences have explored the role of microRNAs (miRNAs) in the immunoregulatory functions of epithelial cells (ECs). The study highlights how ECs play a crucial role in immune responses and how dysregulated EC function can contribute to various diseases. The research emphasizes the potential of miRNA-based therapies in improving human health by regulating gene expression and immune responses. This study provides valuable insights into the molecular mechanisms underlying EC immunoregulatory properties, offering potential strategies for preventing and treating a range of human diseases. [Extracted from the article]

Researchers at South Asian University in New Delhi, India, conducted a study on miRNA-based therapy in the context of Metabolic dysfunction-associated steatotic liver disease (MASLD). The study focused on the role of DDX3 in modulating MASLD progression via miRNA-141-mediated inhibition of Sirt-1 and autophagy. Results indicated that FFA-induced DDX3 upregulated miRNA-141, which targeted Sirt-1 and decreased autophagy. This research sheds light on potential therapeutic targets for chronic liver diseases. [Extracted from the article]

A study conducted by Sun Yat-Sen University in China explored the potential of curcumol, a compound found in a traditional Chinese herb, in inhibiting the growth of hepatocellular carcinoma (HCC) through the miRNA-124/STAT3 pathway. The research identified targets of HCC and curcumol, analyzed the effects of curcumol on HCC cell growth and apoptosis, and found that curcumol downregulated STAT3 expression. The study suggests that curcumol's impact on HCC cell growth inhibition and pro-apoptosis may be linked to the miRNA-124/STAT3 pathway. [Extracted from the article]

A report from China Agricultural University discusses the role of microRNAs (miRNAs) in regulating Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infection in swine. Over 30 miRNAs have been identified as playing a role in PRRSV infection by targeting viral RNA and modulating the host immune response. Understanding the interaction between host miRNAs and PRRSV could lead to the development of new antiviral strategies through miRNA-based therapies. The research highlights the importance of miRNAs in the interplay between the virus and its host, shedding light on potential treatment avenues. [Extracted from the article]

Researchers at Yeungnam University in Gyeongbuk, South Korea, have conducted a study on miRNA-based therapy for detecting pulmonary tuberculosis. The study highlights the potential of miRNAs as biomarkers for disease progression and anti-TB therapy, emphasizing their ability to distinguish between latent and active TB. The research suggests that integrating standard protocols with machine learning could overcome limitations and provide a novel tool for TB diagnostics and therapeutics, facilitating rapid point-of-care testing. This peer-reviewed study offers valuable insights into the use of miRNAs in detecting pulmonary tuberculosis. [Extracted from the article]

A study conducted by researchers at the Oak Ridge Institute of Science and Education focused on the effects of low carbohydrate availability on circulating microRNA profiles following aerobic exercise. The study involved nine male participants and found that low carbohydrate availability altered specific microRNA profiles, particularly miR-375-3p, which plays a role in regulating proteostasis and metabolism during exercise recovery. These findings suggest that unique circulating microRNA targets could serve as potential biomarkers for understanding the impact of carbohydrate availability on exercise recovery. The research was funded by the Military Operational Medicine Research Program and published in Physiological Genomics. [Extracted from the article]

A recent study from Hangzhou Dianzi University in China focused on miRNA-based therapy for breast cancer, a common and heterogeneous disease. The research identified potential drug targets through a system biology analysis of miRNA-gene interaction networks. The study highlighted three specific miRNAs with significant effects on patient prognosis and survival, suggesting four potential drugs for targeted therapy in the future. This research has been peer-reviewed and offers valuable insights into novel drug targets for breast cancer treatment. [Extracted from the article]